Humasis Co

Humasis Co Depreciation & Amortization

The Depreciation & Amortization of Humasis Co (205470.KQ) as of Nov 3, 2026 is 1.73 B KRW. In the previous year, Depreciation & Amortization was 832.90 M KRW — a change of 107.59% (higher).

Depreciation & Amortization

1.73 BKRW

YoY

107.59%

Last updated:

Depreciation & Amortization of Humasis Co is 2024 1.73 B KRW. Depreciation & Amortization of Humasis Co was 2023 832.90 M KRW. It decreases by 107.59% higher compared to the previous year.

The Humasis Co Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2017
68.00 M KRW
Jan 1, 2018
67.00 M KRW
Jan 1, 2019
85.00 M KRW
Jan 1, 2020
98.00 M KRW
Jan 1, 2021
181.88 M KRW
Jan 1, 2022
411.25 M KRW
Jan 1, 2023
832.90 M KRW
Jan 1, 2024
1.73 B KRW
The Humasis Co Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
1.73 BKRW+107.59%
832.90 MKRW+102.53%
411.25 MKRW+126.10%
181.88 MKRW+85.59%
98.00 MKRW+15.29%
85.00 MKRW+26.87%
67.00 MKRW-1.47%
68.00 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Humasis Co Stock analysis

What does Humasis Co do? Humasis Co., Ltd. develops rapid test kits and point-of-care testing instruments for the domestic and overseas markets. The company manufactures immunoquantitative analysis devices, myocardial infarction test equipment, infectious disease detection devices, hormone test devices, and cancer marker test devices. It also researches and develops biomaterials. Humasis sells its products to customers in South Korea and international markets, focusing on healthcare providers and medical institutions that require diagnostic tools for diseases like heart attacks, infections, and cancer. The company's revenue comes from the sale of its diagnostic devices and biomaterials research. Products include immunoquantitative analysis devices, myocardial infarction test equipment, and cancer marker test devices. These are sold to healthcare providers and medical institutions in South Korea and overseas. Humasis targets segments in the medical diagnostics field, particularly for cardiovascular, infectious disease, and oncology applications. Humasis Co., Ltd. operates in the medical device sector, focusing on point-of-care testing solutions. Its product portfolio includes devices for myocardial infarction, infectious diseases, hormones, and cancer markers. The company's sales are driven by demand from hospitals and clinics that need rapid diagnostic tools for patient care. The firm's research and development in biomaterials supports its product offerings in the medical diagnostics market. Humasis Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humasis Co stock

Depreciation & Amortization of Humasis Co is 1.73 B KRW in 2024.

Depreciation & Amortization of Humasis Co changed from 832.90 M KRW to 1.73 B KRW, representing a 107.59% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Humasis Co since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Humasis Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Humasis Co

All Key Metrics — Humasis Co